Analystreport

Rubius Therapeutics, Inc. (NASDAQ: RUBY) had its price target lowered by analysts at Guggenheim from $32.00 to $25.00.

Rubius Therapeutics, Inc.  (RUBY) 
Last rubius therapeutics, inc. earnings: 3/12 07:00 am Check Earnings Report